LORENZ STUDER, director of the Center for Stem Cell Biology at Memorial Sloan Kettering Cancer Center, was named a fellow by the MacArthur Foundation.
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
